Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States
J. Med. Chem., 2016, 59 (10), pp 4948–4964
DOI: 10.1021/acs.jmedchem.6b00306
Publication Date (Web): May 4, 2016
Copyright © 2016 American Chemical Society
*Phone: +1-617-621-2341. E-mail: Wei-Sheng.Huang@ariad.com.
Abstract
In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.
This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib.
A unique structural feature of brigatinib is a phosphine oxide,
an overlooked but novel hydrogen-bond acceptor
that drives potency and selectivity in addition to favorable ADME properties.
Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Brigatinib represents the most clinically advanced phosphine oxide-containing drug candidate to date and is currently being evaluated in a global phase 2 registration trial.
Citation data is made available by participants in CrossRef's Cited-by Linking service. For a more comprehensive list of citations to this article, users are encouraged to perform a search in SciFinder.
- Gregory R. Ott
, Mangeng Cheng, Keith S. Learn, Jason Wagner, Diane E. Gingrich, Joseph G. Lisko, Matthew Curry, Eugen F. Mesaros, Arup K. Ghose, Matthew R. Quail, Weihua Wan, Lihui Lu, Pawel Dobrzanski, Mark S. Albom, Thelma S. Angeles, Kevin Wells-Knecht, Zeqi Huang, Lisa D. Aimone, Elizabeth Bruckheimer, Nathan Anderson, Jay Friedman, Sandra V. Fernandez, Mark A. Ator, Bruce A. Ruggeri, and Bruce D. DorseyJournal of Medicinal Chemistry 2016 59 (16), 7478-7496 - Timothy P. HeffronJournal of Medicinal Chemistry 2016 Article ASAP
Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core
Mei Han, Chengyan Wang, Yinchun Ji, Zilan Song, Li Xing, Yi Su, Xisheng Wang, Ao Zhang, Jing Ai, Meiyu GengBioorganic & Medicinal Chemistry Letters 2016 26 (22), 5399-5402Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer
Shirish M GadgeelThe Lancet Oncology 2016 ,ALK alterations and inhibition in lung cancer
Tri Le, David E. GerberSeminars in Cancer Biology 2016 ,
0 件のコメント:
コメントを投稿